Boston launches Taxus Element in Europe
This article was originally published in Clinica
Executive Summary
Boston Scientific has launched its third-generation drug-eluting stent, Taxus Element, in the EU and other countries that recognise the CE mark. Boston CE marked the paclitaxel-eluting device for use in patients including those with diabetes, last month (www.clinica.co.uk, 14 May 2010). The firm CE marked its Promus Element everolimus-eluting stent, which uses the same platinum chromium alloy and strut design as Taxus Element, in October 2009. Boston expects US FDA approval for Taxus Element in mid-2011, and for Promus Element a year later. Japanese approval for Taxus Element is slated for late 2011 or early 2012, and for Promus Element in mid-2012.
You may also be interested in...
ITF Has A Fight On Its Hands In Duchenne
The group’s new muscular dystrophy pill seems unlikely to cut into Sarepta’s sales.
AbbVie Needs To Freshen Up
With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.
AstraZeneca Pays $2bn To Keep Up With The Joneses
Bristol Myers Squibb and Lilly have recently done billion-dollar radiopharmaceuticals deals, and now the UK group wants a piece of the market. But can it make its Fusion fusion work?